IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia
Jiang, Hao1; Liang, Gong-wen2; Huang, Xiao-jun1; Jiang, Qian1; Han, Sheng2; Shi, Lu-wen2; Zhu, Hong-hu1
关键词Acute Promyelocytic Leukemia Medical Costs Arsenic Retinoic Acid
刊名LEUKEMIA RESEARCH
2015-12-01
DOI10.1016/j.leukres.2015.09.007
39期:12页:1319-1324
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]ACUTE MYELOID-LEUKEMIA ; TRANS-RETINOIC ACID ; REMISSION INDUCTION ; TETRA-SULFIDE ; TRIOXIDE ; THERAPY ; DIFFERENTIATION ; CHEMOTHERAPY
英文摘要

We have demonstrated that oral arsenic (Realgar-Indigo naturalis formula, RIF) plus all-trans retinoic acid (ATRA) is not inferior to intravenous arsenic trioxide (ATO) plus ATRA as the first-line treatment of acute promyelocytic leukemia (APL). To compare the cost-effectiveness of oral and intravenous arsenic, we analyzed the results of 30 patients in each group involved in a randomized controlled trial at our center. The median total medical costs were $13,183.49 in the RIF group compared with $24136.98 in the ATO group (p <0.0001). This difference primarily resulted from the different costs of induction therapy (p = 0.016) and maintenance treatment (p < 0.0001). The length of hospitalization for the RIF group was significantly lower than that for the ATO group (24 vs. 31 days, p <0.0001) during induction therapy. During maintenance treatment, the estimated medical costs were $2047.14 for each patient in the RIF group treated at home compared with $11273.81 for each patient in the ATO group treated in an outpatient setting (p <0.0001). We conclude that oral RIF plus ATRA significantly reduced the medical costs and length of hospital stay during induction and remission therapy compared with ATO plus ATRA in APL patients. (C) 2015 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000365335200003
项目编号81370639 ; 81170483 ; Z111107067311070 ; Z141107002514004 ; Z141100000214011 ; 2012AA02A505
资助机构National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission ; National High-tech R&amp ; D Program (863 Program)
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54014
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
作者单位1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
2.Peking Univ, Dept Pharm Adm & Clin Pharm, Hlth Sci Ctr, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Hao,Liang, Gong-wen,Huang, Xiao-jun,et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia[J]. LEUKEMIA RESEARCH,2015,39(12):1319-1324.
APA Jiang, Hao.,Liang, Gong-wen.,Huang, Xiao-jun.,Jiang, Qian.,Han, Sheng.,...&Zhu, Hong-hu.(2015).Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.LEUKEMIA RESEARCH,39(12),1319-1324.
MLA Jiang, Hao,et al."Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia".LEUKEMIA RESEARCH 39.12(2015):1319-1324.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Hao]的文章
[Liang, Gong-wen]的文章
[Huang, Xiao-jun]的文章
百度学术
百度学术中相似的文章
[Jiang, Hao]的文章
[Liang, Gong-wen]的文章
[Huang, Xiao-jun]的文章
必应学术
必应学术中相似的文章
[Jiang, Hao]的文章
[Liang, Gong-wen]的文章
[Huang, Xiao-jun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。